Why Avalo Therapeutics Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Lisa Levin
Avalo Therapeutics, Inhibikase Therapeutics, PolyPid, WeTrade Group, Gaucho Group Holdings, BIO-Key International, Prosomnus, Renovaro Biosciences, Rail Vision, and Eargo stocks are trading higher in pre-market due to various reasons including higher-than-expected earnings, completion of studies, maintained ratings, and new product launches. Meanwhile, Modular Medical, OpGen, Recruiter.Com Group, 1895 Bancorp of Wisconsin, BioNexus Gene Lab, F45 Training Holdings, Lytus Technologies Holdings, Sidus Space, Smart for Life, and Synlogic stocks are trading lower due to reasons such as partnerships, downgrades, bankruptcy concerns, offerings, and delisting plans.
August 18, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avalo Therapeutics shares surged 24.99% in pre-market trading after reporting higher-than-expected quarterly earnings.
Higher-than-expected earnings typically lead to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Inhibikase Therapeutics shares rose 8.45% in pre-market trading after the company announced the completion of its 501 bioequivalence study of IkT-001Pro.
Completion of studies often leads to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Modular Medical shares tanked 15.44% in pre-market trading after the company announced a partnership with Phillips-Medisize to expand insulin delivery alternatives.
Partnerships can have a negative impact on the stock price if investors perceive the partnership as risky or not beneficial.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
OpGen shares fell 13.16% in pre-market trading after HC Wainwright analysts downgraded the stock amid bankruptcy concerns.
Downgrades and bankruptcy concerns typically lead to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100